AIMS/HYPOTHESIS: Highly active antiretroviral therapy (HAART) in patients infected with human immunodeficiency virus (HIV) is associated with a poorly understood lipodystrophic and hypertriglyceridaemic syndrome, which resembles Cushing's syndrome, but in which plasma cortisol is not elevated. We tested the hypothesis that this HAART-associated lipodystrophy is explained by increased local regeneration of cortisol from inactive cortisone within adipose tissue, catalysed by the enzyme 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1). METHODS: In this cross-sectional study, a previously described cohort of 30 HIV-infected patients with lipodystrophy were compared with 13 HIV-infected patients without lipodystrophy. Intra-abdominal and subcutaneous adipose tissue were quantified using magnetic resonance imaging. Gene expression in subcutaneous fat was measured using real-time PCR. Urine cortisol and its metabolites were analysed by gas chromatography/mass spectrometry. RESULTS: Patients with lipodystrophy had significantly higher 11beta-HSD1 mRNA concentrations (relative to beta2-microglobulin mRNA) in subcutaneous adipose tissue than non-lipodystrophic patients (0.29+/-0.20 vs 0.09+/-0.07, p=0.0004) and higher ratios of urinary cortisol : cortisone metabolites. Adipose tissue 11beta-HSD1 mRNA correlated with multiple features of insulin resistance and with mRNA concentrations for glucocorticoid receptor and angiotensinogen. CONCLUSIONS/ INTERPRETATION: In adipose tissue of patients with HAART-associated lipodystrophy, 11beta-HSD1 mRNA is increased and its concentration is correlated with features of insulin resistance. We suggest that increased adipose tissue 11beta-HSD1 may explain the pseudo-Cushing's features in patients with HAART-associated lipodystrophy, and is a potential therapeutic target.
AIMS/HYPOTHESIS: Highly active antiretroviral therapy (HAART) in patients infected with human immunodeficiency virus (HIV) is associated with a poorly understood lipodystrophic and hypertriglyceridaemic syndrome, which resembles Cushing's syndrome, but in which plasma cortisol is not elevated. We tested the hypothesis that this HAART-associated lipodystrophy is explained by increased local regeneration of cortisol from inactive cortisone within adipose tissue, catalysed by the enzyme 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1). METHODS: In this cross-sectional study, a previously described cohort of 30 HIV-infectedpatients with lipodystrophy were compared with 13 HIV-infectedpatients without lipodystrophy. Intra-abdominal and subcutaneous adipose tissue were quantified using magnetic resonance imaging. Gene expression in subcutaneous fat was measured using real-time PCR. Urine cortisol and its metabolites were analysed by gas chromatography/mass spectrometry. RESULTS:Patients with lipodystrophy had significantly higher 11beta-HSD1 mRNA concentrations (relative to beta2-microglobulin mRNA) in subcutaneous adipose tissue than non-lipodystrophic patients (0.29+/-0.20 vs 0.09+/-0.07, p=0.0004) and higher ratios of urinary cortisol : cortisone metabolites. Adipose tissue 11beta-HSD1 mRNA correlated with multiple features of insulin resistance and with mRNA concentrations for glucocorticoid receptor and angiotensinogen. CONCLUSIONS/ INTERPRETATION: In adipose tissue of patients with HAART-associated lipodystrophy, 11beta-HSD1 mRNA is increased and its concentration is correlated with features of insulin resistance. We suggest that increased adipose tissue 11beta-HSD1 may explain the pseudo-Cushing's features in patients with HAART-associated lipodystrophy, and is a potential therapeutic target.
Authors: J W Tomlinson; J Moore; M S Cooper; I Bujalska; M Shahmanesh; C Burt; A Strain; M Hewison; P M Stewart Journal: Endocrinology Date: 2001-05 Impact factor: 4.736
Authors: Y Kotelevtsev; M C Holmes; A Burchell; P M Houston; D Schmoll; P Jamieson; R Best; R Brown; C R Edwards; J R Seckl; J J Mullins Journal: Proc Natl Acad Sci U S A Date: 1997-12-23 Impact factor: 11.205
Authors: Deborah J Wake; Eva Rask; Dawn E W Livingstone; Stefan Söderberg; Tommy Olsson; Brian R Walker Journal: J Clin Endocrinol Metab Date: 2003-08 Impact factor: 5.958
Authors: Katja Kannisto; Jussi Sutinen; Elena Korsheninnikova; Rachel M Fisher; Ewa Ehrenborg; Karl Gertow; Antti Virkamäki; Tuulikki Nyman; Hubert Vidal; Anders Hamsten; Hannele Yki-Järvinen Journal: AIDS Date: 2003-08-15 Impact factor: 4.177
Authors: K K Miller; P A Daly; D Sentochnik; J Doweiko; M Samore; N O Basgoz; S K Grinspoon Journal: Clin Infect Dis Date: 1998-07 Impact factor: 9.079
Authors: Mario Kratz; Jonathan Q Purnell; Patricia A Breen; Katherine K Thomas; Kristina M Utzschneider; Darcy B Carr; Steven E Kahn; James P Hughes; Elizabeth A Rutledge; Brian Van Yserloo; Michi Yukawa; David S Weigle Journal: J Clin Endocrinol Metab Date: 2007-12-18 Impact factor: 5.958
Authors: Mark Nixon; Deborah J Wake; Dawn E Livingstone; Roland H Stimson; Cristina L Esteves; Jonathan R Seckl; Karen E Chapman; Ruth Andrew; Brian R Walker Journal: Diabetes Date: 2012-02-22 Impact factor: 9.461